POLBF News and Press, Poolbeg Pharma plc Ord GBP 0.0002 From 11/02/23

(NewsDirect) Proactive Research Analyst Daniel Appiah speaks to Thomas Warner at the London Studio after publishing a new research note on clinical-stage biopharmaceutical company Poolbeg Pharma. Appiah starts by explaining the scale of the opportunity that Poolbeg is pursuing with it...

Notice of POLB 001 Oncology Programme Update Meeting LONDON, UK / ACCESSWIRE / November 1, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it will host a...

(NewsDirect) Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing the pharma & biotech company has signed a new collaboration agreement with an unspecified NASDAQ-listed biopharma company. He explains that the co...

2023-10-17 04:33:13 ET More on Poolbeg Pharma Historical earnings data for Poolbeg Pharma Financial information for Poolbeg Pharma For further details see: Poolbeg partners with Nasdaq-listed Biopharma on its oral delivery platform

Poolbeg Pharma Partners with a Nasdaq-Listed Biopharma Company on its Oral Delivery Platform Strategic collaboration focussed on the development of an optimised drug for a metabolic condition using Poolbeg's licensed oral delivery technology Collaboration may expand to a full licensing ...

Positive Conclusion Reached in Immunomodulator I Patent Opposition Patent opposition hearing cancelled LONDON, UK / ACCESSWIRE / September 29, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ('Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company targeting diseases with a ...

Important step in continued protection of Poolbeg's patent family LONDON, UK / ACCESSWIRE / September 19, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that ...

(NewsDirect) Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing the pharma & biotech's interim results for the six months to 30 June 2023. Skillington highlights Poolbeg's "healthy" financial position and attribute...

Significant progress made and well positioned for future growth LONDON, UK / ACCESSWIRE / September 13, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need,announces its una...

(NewsDirect) Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington and CytoReason co-founder and CEO David Harel speak to Thomas Warner from Proactive after announcing what they call a "significant breakthrough" in their world-first influenza Artificial Intelligence ('AI') Pro...